PRECIGEN, INC.·4

Mar 16, 5:07 PM ET

KINDLER JEFFREY B 4

4 · PRECIGEN, INC. · Filed Mar 16, 2026

Research Summary

AI-generated summary of this filing

Updated

Precigen (PGEN) Director Jeffrey Kindler Receives 71,839 Shares

What Happened

  • Jeffrey B. Kindler, a director of Precigen, had 71,839 restricted stock units (RSUs) vest and convert into 71,839 shares on March 13, 2026 (transaction code M — exercise/conversion of derivative). The filing shows an acquisition of 71,839 shares and a simultaneous disposition of 71,839 shares at $0 (derivative), indicating the delivered shares were not sold for cash.
  • No cash proceeds are reported for the disposition (price shown as $0); the acquisition price is listed as N/A. The filing does not disclose a cash value or the number of shares retained by Kindler after the transactions in the summary provided.

Key Details

  • Transaction date: March 13, 2026 (reported on Form 4 filed March 16, 2026) — filing appears timely (within the required reporting window).
  • Transactions: 71,839 shares acquired via conversion of RSUs (M); 71,839 shares disposed at $0 (derivative).
  • Footnotes: F1 — each RSU equals a contingent right to one Precigen common share; F2 — the RSUs vested in full on March 13, 2026.
  • Shares owned after transaction: Not specified in the provided filing summary.
  • Likely tax treatment: The simultaneous disposition at $0 commonly reflects company withholding or surrender of shares to cover tax withholding or related obligations (the filing does not explicitly state the reason).

Context

  • These transactions reflect RSU vesting and conversion rather than an open-market buy or sale. When RSUs vest, insiders receive shares; companies often withhold or accept surrendered shares to satisfy tax withholding, which is routine and does not necessarily indicate a market view.
  • Transaction code M denotes exercise or conversion of a derivative (here, RSUs converting into common stock). This is informational for investors but is typically neutral compared with outright purchases or sales.

Insider Transaction Report

Form 4
Period: 2026-03-13
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-13+71,839202,100 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F2]
    2026-03-1371,8390 total
    Common Stock (71,839 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
  • [F2]The RSUs vested in full on March 13, 2026.
Signature
/s/ Jeffrey B. Kindler, by Donald P. Lehr, as attorney-in-fact|2026-03-16

Documents

1 file
  • 4
    ownership.xmlPrimary

    FORM 4